Belgian drug discovery company Galapagos NV (GLPG.BT) Wednesday said it has expanded its drug alliance with Merck & Co. Inc. (MRK) to include drugs that could treat atherosclerosis, the hardened arteries that cause heart attacks and strokes.

MAIN FACTS:

-Galapagos' alliance milestones will more than double to EUR400 million, plus royalties on worldwide sales.

-Galapagos already works with Merck on diabetes and obesity drug development.

Company Web site: www.glpg.com

Company Web site: www.merck.com

-By Brussels Bureau, Dow Jones Newswires; +322 741 1480;